OSE Immunotherapeutics (France)

company in Paris, France

ISIN FR0012127173 LEI 969500HIUWVGY6NZSM05
Follow OSE Immunotherapeutics (France) Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €2.6M −96.3% vs prior year
Net income −€37.7M −200.7% vs prior year
EPS, diluted −€1.69 −215.8% vs prior year
Operating cash flow −€34M −170.3% vs prior year
Revenue by fiscal year
€10.4M
€26.3M
€2.2M
€69.9M
€2.6M
FY20 FY21 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−€50M€0€50M€100MFY20FY21FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€2.6M−€37.7M
FY24€69.9M€37.4M
FY23€2.2M−€23M
FY21€26.3M−€16.9M
FY20€10.4M−€16.6M
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY20FY21FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1431.3%−1439.1%
FY2462.6%53.6%
FY23−1032.2%−1032.9%
FY21−63.2%−64.1%
FY20−182%−158.7%
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • OSE Immunotherapeutics (France)
  • Healthcare median
−1500%−1000%−500%0%500%FY20FY21FY23FY24FY25
Show the numbers
YearOSE Immunotherapeutics (France)Healthcare median
FY25−1439.1%−30.6%
FY2453.6%−47%
FY23−1032.9%−58%
FY21−64.1%−71.9%
FY20−158.7%−62.2%